Patrick Micke and Carina Strell’s groups investigated 305 clinical samples of NSCLC patients using isPLA in addition to the classical IHC.
PD1/PD-L1 interaction as a superior predictor for response to immune checkpoint therapy
Patrick Micke and Carina Strell’s groups investigated 305 clinical samples of NSCLC patients using isPLA in addition to the classical IHC.
They found that only about half of the patients who were positive for both PD1 and PD-L1 also exhibited the PD1/PD-L1 interaction. Furthermore, unlike PD-L1 expression alone, a high number of the interactions were associated with improved survival in patients that had undergone ICT compared to matched ICT-naive controls. The higher the isPLA score, the more complete response to therapy the patients had, suggesting that the PD1/PD-L1 interaction may be superior to the gold standard PD-L1 as a stratifying biomarker.
They found that only about half of the patients who were positive for both PD1 and PD-L1 also exhibited the PD1/PD-L1 interaction. Furthermore, unlike PD-L1 expression alone, a high number of the interactions were associated with improved survival in patients that had undergone ICT compared to matched ICT-naive controls. The higher the isPLA score, the more complete response to therapy the patients had, suggesting that the PD1/PD-L1 interaction may be superior to the gold standard PD-L1 as a stratifying biomarker.
Click the image below to view the poster as a PDF in a new tab.
Read more
Was this presentation interesting? We have more of them! Go back to the video presentation collection’s page.